Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.30 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.30 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519062 | 0.79 | CXCR2 (0.39) | CXCR1CXCR2ENPP2ORAI1ORAI2 | |
| SCHEMBL15780079 | 0.79 | CXCR1 (0.41) | CXCR1CXCR2LIPGSMN1; SMN2 | |
| SCHEMBL456808 | 0.79 | CXCR2 (0.39) | CXCR1CXCR2ENPP2ORAI1ORAI2 | |
| SCHEMBL19150350 | 0.77 | CXCR1 (0.38) | CXCR1CXCR2ENPP2ORAI1ORAI2 | |
| SCHEMBL9938058 | 0.77 | MPO (0.41) | CXCR1CXCR2ENPP2 | |
| SCHEMBL8859850 | 0.76 | PSEN1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL3769431 | 0.76 | MPO (0.40) | CXCR1CXCR2 | |
| SCHEMBL31758459 | 0.74 | SLC6A4 (0.47) | CXCR1CXCR2SMN1; SMN2 | |
| SCHEMBL18037330 | 0.74 | ENPP2 (0.38) | CXCR1CXCR2ENPP2ORAI1ORAI2 | |
| SCHEMBL13197054 | 0.74 | GABRA1 (0.38) | CXCR1CXCR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920085-B2 | Boronic acid conjugates of oligonucleotide analogues | SAREPTA THERAPEUTICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |